AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-03. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
== Diagnosis == While Sjögren's disease is one of the most common autoimmune diseases, it has no specific and non-invasive diagnostic tests. Diagnosing Sjögren's disease is complicated by the range of symptoms that a patient may manifest, and the similarity between symptoms of Sjögren's disease and those of other conditions. Also, patients with Sjögren’s symptoms approach different specialities for treatment, which can make diagnosis difficult. Since dry eyes and dry mouth are very common symptoms, and frequently occur in people over 40, affected people may believe the symptoms are age-related. Therefore, they often ignore them. Some medications can cause symptoms similar to those of Sjögren's disease.
Among these, the recently described (2023) fungus Tremella parietinae is found exclusively on X. parietina, where it induces the formation of convex, orange to yellow galls within the hymenium of its apothecia. This fungus is known from several European countries—including Austria, Spain, and Sweden—and likely has a broader distribution wherever its host occurs. Another lichenicolous fungus, Tremella occultixanthoriae, parasitizes X. parietina but develops on the lower surface of the thallus and produces four-celled basidia. Both fungi belong to a broader complex of Tremella species that specialize in infecting Teloschistaceae lichens, often with strict host specificity. Some common saprotrophic fungi not typically associated with lichens have also been found colonizing X. parietina. These include Epicoccum nigrum, appearing as dark purple-brown hemispherical heaps on the surface of apothecial discs, and Periconia digitata, which forms distinctive stalked spherical heads resembling tiny pins on the apothecia and thallus. The environmental conditions that trigger such extensive fungal colonization remain unclear, although factors like prolonged snow cover, high rainfall, or other environmental stressors may initially weaken the lichen, making it susceptible to fungal invasion. Another lichenicolous fungus is Arthonia parietinaria, which was long misidentified as Arthonia molendoi or A. epiphyscia. This species forms mat black, dull ascomata that are arranged in large groups of up to 20–30 (sometimes 50) on the thallus surface of X.
==== Vascular tissue ==== High rates of cardiovascular disease creates a high demand for grafts for vascular bypass surgery, especially small-diameter grafts which prevent occlusion. Modifying vascular tissue grafts with RGD has been shown to inhibit platelet adhesion, improve cell infiltration and enhance endothelialization. There have also been efforts to regenerate damaged heart tissues by applying cardiac patches following myocardial infarction. The addition of RGD onto a cardiac tissue scaffold has been shown to promote cell adhesion, prevent apoptosis and enhance tissue regeneration. RGD peptide has also been used to improve endothelial cell adhesion and proliferation on synthetic heart valves.
Sources: en.wikipedia.org
=== Cell migration === Cell migration is essential for the formation of granulation tissue. The early stage of granulation tissue is dominated by a HA-rich extracellular matrix, which is regarded as a conducive environment for the migration of cells into this temporary wound matrix. HA provides an open hydrated matrix that facilitates cell migration, whereas, in the latter scenario, directed migration and control of related cell mechanisms are mediated via the specific cell interaction between HA and cell surface HA receptors. It forms links with several protein kinases associated with cell locomotion, for example, extracellular signal-regulated kinase, focal adhesion kinase, and other non-receptor tyrosine kinases. During fetal development, the migration path through which neural crest cells migrate is rich in HA. HA is closely associated with the cell migration process in granulation tissue matrix, and studies show that cell movement can be inhibited, at least partially, by HA degradation or blocking HA receptor occupancy. By providing the dynamic force to the cell, HA synthesis has also been shown to associate with cell migration. Basically, HA is synthesized at the plasma membrane and released directly into the extracellular environment. This may contribute to the hydrated microenvironment at sites of synthesis, and is essential for cell migration by facilitating cell detachment.
== Industrial uses == Penicillium digitatum is used as a biological tool during the commercial production of latex agglutination kits. Latex agglutination detects Aspergillus and Penicillium species in foods by attaching antibodies specific for the extracellular polysaccharide of P. digitatum to 0.8 μm latex beads. This method has been successful in detecting contamination of grains and processed foods at a limit of detection of 5–10 ng/mL of antigen. In comparison to other detection assays, the latex agglutination assay exceeds the detection limit of the Enzyme-linked immunosorbent assay (ELISA) and is as effective in detecting Aspergillus and Pencillium species as the ergosterol production assay. However, the latter displays an increased ability to detect Fusarium species, when compared to the latex agglutination assay.
==== Declined ==== Grant Moody, Bexar County commissioner from the 3rd precinct Kyle Sinclair, former vice chair of the Bexar County Republican Party, nominee for the 20th district in 2022, and candidate for the 28th district in 2024 (ran in the 21st district) Marc Whyte, San Antonio city councilor from the 10th district (2023–present) and candidate for Texas's 121st House of Representatives district in 2018 (endorsed Lujan)
=== Motility disorders === Several disorders affect the motility of food as it travels down the esophagus. This can cause difficult swallowing, called dysphagia, or painful swallowing, called odynophagia. Achalasia refers to a failure of the lower esophageal sphincter to relax properly, and generally develops later in life. This leads to progressive enlargement of the esophagus, and possibly eventual megaesophagus. A nutcracker esophagus refers to swallowing that can be extremely painful. Diffuse esophageal spasm is a spasm of the esophagus that can be one cause of chest pain. Such referred pain to the wall of the upper chest is quite common in esophageal conditions. Sclerosis of the esophagus, such as with systemic sclerosis or in CREST syndrome may cause hardening of the walls of the esophagus and interfere with peristalsis.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.